Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 3Observational 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Non-small Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Blood Specimen Collection 135Surveys and Questionnaires 132Specimen Handling 57Observation 55Radiotherapy 43Interviews as Topic 35Surgical Procedures, Operative 31Biopsy 30Drug Therapy 30Data Collection 25Magnetic Resonance Spectroscopy 25Nivolumab 21Immune Checkpoint Inhibitors 18Watchful Waiting 18Standard of Care 17Therapeutics 17Immunotherapy 16Magnetic Resonance Imaging 16trastuzumab deruxtecan 14Liquid Biopsy 13Restraint, Physical 13Tomography, X-Ray Computed 13palbociclib 13Radiosurgery 12enzalutamide 12Focus Groups 11Hematologic Tests 11apalutamide 11darolutamide 11pembrolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × taletrectinib × 1 year × Clear all
NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting
50 enrolled
Thoracic

Non-small Lung Cancer

NCT07008287 2025-07-22

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Innovent Biologics (Suzhou) Co. Ltd.

Recruiting
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡